Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma—a phase II trial of the AIO study group (AIO STO 0321)

BackgroundEsophagogastric adenocarcinoma (EGA) presents a substantial global health challenge as the number of cases continues to rise. The current standard approach for treating localized EGA involves a combination of triplet chemotherapy, which consists of a platinum compound, a fluoropyrimidine,...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Joseph Tintelnot, Alexander Stein, Salah-Eddin Al-Batran, Thomas Ettrich, Thorsten Götze, Barbara Grün, Georg Martin Haag, Vera Heuer, Ralf-Dieter Hofheinz, Nils Homann, Tobias Sebastian Bröring, Mariana Santos Cruz, Annika Kurreck, Sylvie Lorenzen, Nicolas Moosmann, Christian Müller, Markus Schuler, Gabriele Siegler, Mascha Binder, Eray Gökkurt
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Frontiers Media S.A. 2023-10-01
Serie:	Frontiers in Oncology
Soggetti:	esophagogastric adenocarcinoma HER2 trastuzumab pembrolizumab perioperative
Accesso online:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1272175/full
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!